![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
EDITORIAL article
Front. Immunol. , 18 March 2022
Sec. Autoimmune and Autoinflammatory Disorders
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.725090
This article is part of the Research Topic Immunomodulatory Roles of Extracellular Vesicles in Autoimmune Diseases View all 14 articles
Editorial on the Research Topic
Immunomodulatory Roles of Extracellular Vesicles in Autoimmune Diseases
Autoimmune diseases reflect a breakdown in self-tolerance that results from defects in our complex immune system. The mechanisms are multifactorial and include a combination of cellular, genetic, epigenetic, and molecular components that result in phenotypic inflammatory responses in a variety of tissues and organs. Extracellular vesicles (EVs) have been shown to play a role in immunomodulation and pathogenesis of autoimmune diseases. This Research Topic provides a few reviews and manuscripts highlighting the immunomodulation and therapeutic potential of EVs in a variety of autoimmune diseases including rheumatoid arthritis (RA), Sjögren’s syndrome (SS), bullous pemphigoid (BP), type 1 diabetes mellitus (T1DM), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), and antiphospholipid-associated diseases (APS).
RA is a chronic autoimmune disease affecting joints via pain, inflammation, loss of mobility, and eventually the erosion of joints, with no effective treatment to date. As reviewed in this Research Topic, extracellular vesicles derived from mesenchymal stem cells (MSCs) are more stable, less toxic, and more effective at transferring nucleic acids, proteins, and lipids from parent to recipient cells. MSC-EVs are multipotent progenitor cells with immunomodulatory properties that can be easily obtained and expanded rapidly, as well as a potential therapeutic strategy for RA (Liu et al.).
SS is a chronic multi-organ autoimmune disorder primarily effecting the exocrine glands. As reviewed in this Research Topic, ongoing extracellular vesicle studies in SS have been limited to tears and saliva, neglecting the investigation of novel biomarkers and potential therapeutic effects of EVs in SS from effected tissues and organs (Huang et al.).
BP is an autoimmune disorder of the skin characterized by blistering, urticarial lesions, and itching. In this retrospective study, Chen et al. demonstrated that inpatient BP patients are at risk of infectious complications, leading to comorbidities, due to higher doses of corticosteroids. They compared the risk factors of infection of inpatients and outpatients to develop preventative and treatment strategies.
Liu and Li proposed the potential use of EVs for the understanding the proinflammatory roles of BP for diagnostics. As shown in studies, concentrations of cytokines are elevated in BP, and it is speculated that EVs can transport the pathogenic autoantibodies associated with BP which can then be released and stimulate a favorable immune response.
In this study, Giri et al. investigated the changes in the relative composition of the vesiculome as well as the partition of the candidate autoantigen insulin and immunostimulatory miRNA sequences inside apoptotic bodies, microvesicles, and exosome subpopulations derived from equal amounts of healthy and stressed beta cells and their impact on innate immune responses. They identified that beta small extracellular vesicles (sEVs) have been shown to drive innate and adaptive pro-diabetogenic immune responses, with a limitation in the molecular and functional diversity of EVs in the beta cell’s secretome, which necessitates further exploration.
In this review, Zhang et al. reviewed recent studies examining the roles of EVs in RA and SLE, both chronic autoimmune diseases but SLE affects multiple organs, in understanding their pathogenesis, diagnosis, and therapeutic potentials.
Neutrophils play a central role in our immune defense system with pathogen clearance, immune regulation, and disease pathology. Song et al. describe the role of neutrophil extracellular traps (NETs) in detail, as novel therapeutic targets for RA.
Hegewald et al. detail the roles of sEVs carrying microRNAs (miRs) in RA. The sEVs from synovial fluid promote osteoclast differentiation, attributed to high levels of extracellular miR-574-5p. They continue to demonstrate that enhanced osteoclast maturation is mediated by toll-like receptor (TLR) 7/8 signaling due to the mechanism of miR-574-5p binding. This is a novel finding of the role of miR-574-5p which may provide a therapeutic approach to protect osteoclast-mediated bone destruction in RA.
In this comprehensive study, Wu et al. identified granulocytic-myeloid suppressor cell (G-MDSC)-derived EVs as a potential mediator in the treatment of mice with collagen-induced arthritis (CIA). The initial finding demonstrated lower arthritis index values and decreased inflammatory cell infiltration, indicating an alteration of the humoral environment by mediating high levels of prostaglandin E2 (PGE2), by production of IL-10+ B cells.
T1DM is caused by an immune-mediated destruction of pancreatic beta cells. Pang et al. detail a comprehensive review on the understanding of how exosomes can 1) enable the underlying pathogenic mechanisms of T1DM, 2) provide novel biomarkers for T1DM diagnosis, and 3) lead to the development of new TIDM therapeutic strategies.
In this extensive study, Tian et al. have identified the immunoregulatory property of exosomes derived from olfactory ecto-mesenchymal stem cells (OE-MSCs) and their immunomodulation capacity to ameliorate disease severity in IBD mice, primarily by regulating Th-cell immune responses. Their study suggests OE-MSC exosomes are a potential novel cell-free therapy for targeting inflammatory diseases.
APS is a systemic autoimmune disorder in which the body’s immune system makes antibodies that attack phospholipids which can lead to thrombosis and/or pregnancy complications. Tan et al. conducted human and mouse studies to demonstrate that APS exosomes are a key factor in the pathogenesis of APS and that apolipoprotein H (APOH) is a protein that impairs vascular biological function. They concluded APS and APOH exosomes impair vascular development (pathogenesis) and lead to pregnancy complications, providing new targets for therapeutic intervention.
Tolomeo et al. compared the effects of MSCs and of MSC-EV administration in mice with colitis induced by dextran sulfate sodium (DSS). They reported naïve MSCs and induced MSC administration resulted in poor clinical and histological outcomes, with pro-inflammatory polarization of intestinal macrophages. However, when the mice were treated with induced EVs, there was decreased intestinal fibrosis and angiogenesis and a striking increase in intestinal expression of Mucin 5ac, suggesting improved epithelial function. EVs demonstrated a beneficial effect, more predictable behavior, a safer therapeutic profile, and efficacy with respect to their cells of origin.
This Research Topic has provided examples in which EVs have displayed immunomodulatory roles in autoimmune diseases. In addition, it highlighted and suggested the necessity for future discovery of new targets for therapeutic interventions which will aid in the diagnosis, understanding the mechanisms, and outcomes for a variety of autoimmune diseases.
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
WK is employed by Predicine.
The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
We would like to thank all authors for their contributions to this Research Topic.
Keywords: extracellular vesicles, autoimmune diseases, diagnosis, immunomodulatory, pathogenesis, therapeutics
Citation: Gu Z and Kuo WP (2022) Editorial: Immunomodulatory Roles of Extracellular Vesicles in Autoimmune Diseases. Front. Immunol. 13:725090. doi: 10.3389/fimmu.2022.725090
Received: 14 June 2021; Accepted: 17 February 2022;
Published: 18 March 2022.
Edited and reviewed by:
Raphaela Goldbach-Mansky, National Institutes of Health (NIH), United StatesCopyright © 2022 Gu and Kuo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhifeng Gu, Z3V6aGlmZW5nQDEyNi5jb20=; Winston Patrick Kuo, d2t1b0BwcmVkaWNpbmUuY29t
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.